Genetic Analysis AS general meeting has approved the share exchange with Biohit Oyj
Biohit Oyj Stock Exchange Release January 22, 2016 at 4:00 pm local time (EET)
Genetic Analysis AS general meeting has approved the share exchange with Biohit Oyj. According to the share exchange agreement Biohit Oyj acquires ownership of 18 % of all shares in Genetic Analysis AS. In consideration, Biohit Oyj will issue 350,000 pcs of new Biohit Oyj’s series B shares to Genetic Analysis AS.
Biohit Oyj estimates to register the shares with the Finnish Trade Register by 17th February 2016 and the trading in the shares is expected to commence as of the trading day following the registration. Biohit Oyj’s registration as a shareholder in Genetic Analysis AS is estimated to take place during February 2016.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit Oyj Stock Exchange Release January 5, 2016: Biohit Oyj buys a share of Norwegian Genetic Analysis AS –company with a directed share issue
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Genetic Analysis AS in brief
Genetic Analysis has developed and launched the first bacterial gene-based clinical test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine clinical testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi and Nofima Mat in Ås, Norway. www.genetic-analysis.com/